Oral formulations of budesonide: A novel treatment for inflammatory bowel disease

Drugs of Today

Volumn 44, Issue 11, 2008, Pages 857-863

  Svoboda, R Paul ^a   Patel, Dhaval H ^a   Olden, Kevin W ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; PLACEBO; PREDNISOLONE; PREDNISONE; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; AUTOIMMUNE HEPATITIS; BONE DENSITY; CELIAC DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; COLLAGENOUS COLITIS; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG STRUCTURE; ENTERITIS; HUMAN; LYMPHOCYTIC COLITIS; MICROSCOPIC COLITIS; PRIMARY BILIARY CIRRHOSIS; PROCTITIS; SIDE EFFECT; ULCERATIVE COLITIS;

EID: 60949092457     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.11.1308917     Document Type: Article

References (54)

1. Andus, T., Targan, S.R. Corticosteroids. In: Inflammatory Bowel Disease: From Bench to Bedside. S.R. Targan, F. Shanahan (Eds.). Williams & Wilkins: Baltimore, MD 1993, 487-502.
2. Irving, P.M., Gearry, R.B., Sparrow, M.P., Gibson, P.R. Review article: Appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther 2007, 26(3): 313-29.
3. Rutgeerts, P.J. Review article: The limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001, 15(10): 1515-25.
4. Klingenstein, G., Levy, R.N., Kornbluth, A., Shah, A.K., Present, D.H. Inflammatory bowel disease related osteonecrosis: Report of a large series with a review of the literature. Aliment Pharmacol Ther 2005, 21 (3): 243-9.
5. Stuck, A.E., Minder, C.E., Frey, F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11(6): 954-63.
6. Aberra, F.N., Lewis, J.D., Mass, D., Rombeau, J.L., Osborne, B., Lichtenstein, G.R. Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003, 125(2): 320-6.
7. Munkholm, P., Langholz, E., Davidsen, M., Binder, V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35(3): 360-2.
8. Rogler, G., Meinel, A., Lingauer, A. et al. Glucocorticoid receptors are down-regulated in inflamed colonic mucosa but not in peripheral blood mononuclear cells from patients with inflammatory bowel disease. Eur J Clin Invest 1999, 29(4): 330-6.
9. Toogood, J.H., Frankish, C.W., Jennings, B.H., Baskerville, J.C., Borga, O., Lefcoe, N.M., Johansson, S.A. A study of the mechanism of the anti-asthmatic action of inhaled budesonide. J Allergy Clin Immunol 1990, 85(5): 872-80.
10. Edsbäcker, S., Andersson, T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004, 43(12): 803-21.
11. Miller-Larsson, A., Gustafsson, B., Persson, C.G., Brattsand, R. Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat. Aliment Pharmacol Ther 2001, 15(12): 2019-25.
12. Jonssön, G., Aström, A., Andersson, P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995, 23(1): 137-42.
13. Guengerich, P.P. Cytochrome P450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999, 39: 1-17.
14. Dilger, K., Schwab, M., Fromm, M.F. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 2004, 10(5): 578-83.
15. Ryrteldt, A., Andersson, P., Edsbäcker, S., Tönnesson, M., Davies, D., Pauwels, R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 1982, 122: 86-95.
16. Ryrteldt, A., Edsbäcker, S., Pauwels, R. Kinetics of epimeric glucocorticoid budesonide. Clin Pharmacol Ther 1984, 35(4): 525-30.
17. Edsbäcker, S., Bengtsson, B., Larsson, P., Lundin, P., Nilsson, A., Ulmius, U., Wollmer, P. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther 2003, 17(4): 525-36.
18. Tremaine, W.J., Hanauer, S.B., Katz, S., Winston, B.D., Levine, J.G., Persson, T., Persson, A. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: A randomized place bo-controlled study in the United States. Am J Gastroenterol 2002, 97(7): 1748-54.
19. Greenberg GR, Feagan BG, Martin F. et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331 (13): 836-41.
20. Rutgeerts, P., Löfberg, R., Malchow, H. et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994, 331(13): 842-5.
21. Thomsen, O.O., Cortot, A., Jewell, D. et al. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 1998, 339(6): 370-4.
22. AstraZeneca data on file.
23. Hofer, K.N. Oral budesonide in the management of Crohn's disease. Ann Pharmacother 2003, 37(10): 1457-64.
24. Thomsen, O.O., Cortot, A., Jewell, D. et al. Budesonide and mesalazine in active Crohn's disease: A comparison of the effects on quality of life. Am J Gastroenterol 2002, 97(3): 649-53.
25. Travis, S.P., Stange, E.F., Lémann, M. et al. European evidence based consensus on the diagnosis and management of Crohn's disease: Current management. Gut 2006, 55(Suppl 1): i16-i35.
26. Campieri, M., Ferguson, A., Doe, W., Persson, T., Nilsson, L.G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997, 41(2): 209-14.
27. Sandborn, W.J., Löfberg, R., Feagan, B.C., Hanauer, S.B., Campieri, M., Greenberg, G.R. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: A predetermined pooled analysis of four randomized, doubleblind, placebo-control trials. Am J Gastroenterol 2005, 100(8): 1780-7.
28. Mantazaris, G.J., Petraki, K., Chadio-Iordanides, H. et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology 2002, 122: A-81.
29. Nightingale, J.M. Management of patients with a short bowel. Nutrition 1999, 15: 633-7.
30. Huber, F.X., Hinz, U., Haack, D., Lucas, M., Heuschen, U., Herfarth, C., Stern, J. High pouch output syndrome. Role of mineralocorticoid diagnosis after restorative proctocolectomy. Chirurg 2001, 72: 1446-52.
31. Ecker, K.W., Stallmach, A., Seitz, G., Gierend, M., Greinwald, R., Achenbach, U. Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn's disease. Scand J Gastroenterol 2003, 38(3): 288-93.
32. Ecker, K.W., Stallmach, A., Loffler, J., Greinwald, R., Achenback, U. Long-term treatment of high intestinal output syndrome with budesonide in patients with Crohn's disease and ileostomy. Dis Colon Rectum 2005, 48(2): 237-42.
33. Sutherland, L.R., May, G.R., Shatter, E.A. Sulfasatazine revisited: A meta-analysis of 5-amino-salicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993, 118(7): 540-9.
34. Danielsson, Å., Löfberg, R., Persson, T., Salde, L., Schiöler, R., Suhr, O., Willen, R. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scan J Gastroenterol 1992, 27(1): 9-12.
35. Marshall, J.K., Irvine, E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis. Gut 1997, 40(6): 775-81.
36. Kolkman, J.J., Möllmann, H.W., Möllmann, A.C., Penã, A.S., Greinwald, R., Tauschel, H.D., Hochhaus, G. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today (Bare) 2004, 40(7): 589-601.
37. Löfberg, R., Danielsson, A., Suhr, O. et al. Oral budesonide verses prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996, 110(6): 1713-8.
38. Keller, R., Stoll, R., Foerster, E.G., Gutsche, N., Domschke, W. Oral budesonide therapy for steroid-dependent ulcerative colitis: A pilot trial. Aliment Pharmacol Ther 1997, 11(6): 1047-52.
39. Gionchetti, P., Rizzello, F., Poggioli, G. et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007, 25(10): 1231-6.
40. Rautiainen, H., Karkkainen, P., Karvonen, A.L., Nurmi, H., Pikkarainen, P., Nuutinen, H., Färkkila M. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial. Hepatology 2005, 41 (4): 747-52.
41. Rautiainen, H., Farkkila, M., Neuvonen, M. et al. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. Aliment Pharmacol Ther 2006, 24(11-12): 1545-52.
42. Angulo, P., Jorgensen, R.A., Keach, J.C., Dickson, E.R., Smith, C., Lindor, K.D. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000, 31(2): 318-23.
43. Hempfling, W., Grunhage, F., Dilger, K., Reichel, C., Beuers, U., Sauerbruch, T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003, 38(1): 196-202.
44. Dilger, K., Denk, A., Heeg, M .H., Beuers, U. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology 2005, 41(3): 595-602.
45. Csepregi, A., Rocken, C., Treiber, G., Malfertheiner, P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006, 12(9): 1362-66.
46. Ryan, B.M., Kelleher, D. Refractory celiac disease. Gastroenterology 2000, 119(1): 243-51.
47. Brar, P., Lee, S., Lewis, S., Egbuna, I., Bhagat, G., Green, P.H. Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol 2007, 102(10): 2265-69.
48. Nyhlin, N., Bohr, J., Eriksson, S., Tysk, C. Systematic review: Microscopic colitis. Aliment Pharmacol Ther 2006, 23(11): 1525-34.
49. Wall, G., Schirmer, L., Page, M.J. Pharmacotherapy for microscopic colitis. Pharmacotherapy 2007, 27(3): 425-33.
50. Bonderup, O.K., Hansen, J.B., Birket-Smith, L., Vestergaard, V., Teglbjaerg, P.S., Fallingborg, J. Budesonide treatment of collagenous colitis: A randomized, double blind, placebo controlled trial with morphometric analysis. Gut 2003, 52(2): 248-51.
51. Miehlke, S., Heymer, P., Bethke, B. et al. Budesonide treatment for collagenous colitis: A randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002, 123(4): 978-84.
52. Miehlke, S., Madisch, A., Voss, C. et al. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther 2005, 22(11-12): 1115-9.
53. Sari, I., Altuntas, F., Kocyigit, I. et al. The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol 2007, 82(5): 349-56.
54. Bertz, H., Afting, M., Kreisel, W., Duffner, U., Greinwald, R., Finke, J. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999, 24(11): 1185-9.